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Shigeo Fuji,1 Sung-Won Kim,1 Ken-ichi Yoshimura,2 Hideki Akiyama,3 Shin-ichiro Okamoto,4
Hiroshi Sao,5 Junko Takita,6 Naoki Kobayashi,7 Shin-ichiro Mori1 for the Japan
Marrow Donor ProgramBoth obesity and malnutrition are considered risk factors for complications after bone marrow transplanta-
tion (BMT). To elucidate the impact of pretransplantation body mass index (BMI) on clinical outcome, we
performed a retrospective cohort study with registration data from the Japan Marrow Donor Program
(JMDP). Between January 1998 andDecember 2005, a total of 3935 patients received unrelated BMT through
the JMDP; of these, 3827 patients for whom pretransplantation height and weight data were available were
included in the study. Patients were stratified according to pretransplantation BMI values (low BMI: BMI\18
kg/m2, n5 295; normal BMI: 18 # BMI\25 kg/m2, n5 2906; overweight: 25# BMI\30 kg/m2, n 5 565;
obese: 30 kg/m2# BMI, n5 61). In a univariate analysis, pretransplantation BMI was associated with a signif-
icantly greater risk of grade II-IV acute graft-versus-host disease (GVHD; P 5 .03). Multivariate analysis
showed that pretransplantation BMI tended to be associated with an increased risk of grade II-IV acute
GVHD (P 5 .07). Obesity was associated with an increased risk of infection compared with normal BMI
(odds ratio 5 1.9; 95% confidence interval 5 1.1 to 3.2; P 5 .02). Our findings demonstrate a correlation
between pretransplantation BMI and posttransplantation complications. Although BMI depends strongly
on multiple factors, the effect of obesity on clinical outcome should be evaluated in a prospective study.
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6/j.bbmt.2008.10.029nonrelapse mortality in hematopoietic stem cell trans-
plantation (HSCT). An inferior outcome after alloge-
neic HSCT has been reported in obese adult patients
in both allogeneic [1,2] and autologous HSCT [3-5].
Furthermore, our group recently reported that hyper-
glycemia during the neutropenic period is associated
with an increased risk of acute graft-versus-host dis-
ease (GVHD) and subsequent nonrelapse mortality
[6]. Obesity obviously is associated with an increased
risk of hyperglycemia [7], which can lead to an inferior
outcome after allogeneicHSCT. Recently, obesity was
reported to be associated with low-grade systemic in-
flammation and was identified as a possible risk factor
for autoimmune diseases [8-10]. Alternatively, malnu-
trition has been reported to be associated with an in-
creased risk of early death after allogeneic HSCT
[11,12]. Several reports have noted an association be-
tween malnutrition and a high incidence of infectious
disease in conventional chemotherapy settings [13-15].
Although we can speculate that these infectious
complications may be associated with nonrelapse mor-
tality in HSCT, there is currently no agreement73
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body mass index (BMI) for clinical management. Pre-
vious studies have included various kinds of stem cell
sources, and some have included HSCT with T cell
depletion. The aim of the present study was to retro-
spectively evaluate the impact of pretransplantation
BMI on the clinical outcome after unrelated bone mar-
row transplantation (BMT) for hematologicmalignan-
cies, using registration data from the Japan Marrow
Donor Program (JMDP). The results should provide
insight into how to better manage nutritional support
for patients undergoing HSCT.PATIENTS AND METHODS
A total of 3935 patients with various hematologic
malignancies underwent BMT through the JMDP be-
tween January 1998 and December 2005. Data from
3827 of these patients for whom pretransplantation
height and weight data were available were included
in the present study. Patient characteristics are sum-
marized in Table 1. The median patient age was 39
years (range, 18 to 72 years), and diagnoses included
acute myeloid leukemia (AML; n 5 1165), acute lym-
phoblastic leukemia (ALL; n 5 755), myelodysplastic
syndrome/myeloproliferative disease (MDS/MPD;
n 5 597), malignant lymphoma (ML; n 5 500) and
chronic ML (CML; n 5 576), other leukemia (n 5
69), multiple myeloma (n 5 71), and other (n 5 94).
Standard risk included acute leukemia in first complete
remission (CR1), CML in first chronic phase, MDS in
refractory anemia, and lymphoma in CR1. The rest of
the patients were categorized as a high-risk group.
Bone marrow was the sole stem cell source for trans-
plantation. Total body irradiation (TBI) was used in
2849 patients. GVHD prophylaxis included cyclo-
sporine (CSP)-based (n 5 1520) and tacrolimus
(TAC)-based regimens (n5 2155), or other combina-
tions (n 5 152), with the addition of low-dose antith-
ymocyte globulin (ATG) in 205 patients. Alleles at
the HLA-A, -B, and -DRB1 loci were identified by
high-resolution DNA typing. The median follow-up
period was 565 days. Informed consent was obtained
from patients and donors in accordance with the Dec-
laration of Helsinki, and the study design was ap-
proved by the JMDP’s Institutional Review Board.
The study’s primary endpoints were nonrelapse
mortality at 100 days and 1 year, overall survival at 1
year, and progression-free survival at 1 year. For non-
relapse mortality, an event was death without disease
progression after BMT. For overall survival, an event
was death from any cause after BMT. For progres-
sion-free survival, an event was disease progression
or death after BMT. Secondary endpoints were the in-
cidence of infection (bacterial, viral, fungal, and
others); incidence of lung organ toxicity includinginterstitial pneumonia, adult respiratory distress syn-
drome, bronchiolitis obliterans, pulmonary hemor-
rhage, and others, excluding pneumonia with obvious
infectious diseases; and incidence of hepatic toxicity,
including veno-occlusive disease and drug toxicity.
Acute GVHD was classified as grade 0, I, II, III, or
IV according to established criteria [16]. The probabil-
ity of acute GVHD, nonrelapse mortality rate, overall
survival, progression-free survival, and relapse rate
were estimated using the Kaplan-Meier method.
Death without acute GVHD was treated as censoring
in the analysis of acute GVHD, and death without pro-
gression was treated as censoring in the analysis of re-
lapse. Dichotomous variables between groups were
compared using the c2 test, and survival times were
compared using the log-rank test. An order-restricted
version of the log-rank test (a log-rank trend test) was
used to test ordered differences between the estimated
survival curves. Multivariate analyses were performed
using a logistic regressionmodel or a Cox proportional
hazards model, as appropriate. The following covari-
ates were included in the univariate analysis: BMI
(BMI \ 18 kg/m2, 18 # BMI \ 25 kg/m2, 25 #
BMI\ 30 kg/m2, and 30 kg/m2 # BMI), sex (donor–
recipient pairs), patient age (age \ 30 years, 30 #
age\ 50 years, age $ 50 years), donor age (age\ 40
years, age$ 40 years), type of disease, risk of leukemia
relapse (standard vs high), conditioning (TBI-based vs
non–TBI-based), GVHD prophylaxis (CSP-based vs
TAC-based), genotypic HLA match versus HLA mis-
match, ABO match versus mismatch (major mismatch
vs minor mismatch vs major/minor mismatch vs
match), cell dose in the graft (dose\ 3.0  108/kg,
3.0 # dose\ 5.0  108/kg, $ 5.0  108/kg), and use
of ATG/antilymphocyte globulin (ALG) (ATG/ALG
vs no ATG/ALG). All P values were 2-sided. A P value
\ .05 was considered statistically significant.RESULTS
Patient Characteristics
Table 1 gives the BMI distribution of the study
group. Patients were classified into 4 groups based
on pretransplantation BMI values according to con-
sensus weight designations from the World Health
Organization [17] and the National Heart Lung and
Blood Institute Expert Panel [18], as follows: low
BMI (BMI\ 18 kg/m2; n 5 295), normal BMI (18
# BMI \ 25 kg/m2; n 5 2906), overweight (25 #
BMI\ 30 kg/m2; n 5 565), and obesity (30 kg/m2 #
BMI; n 5 61). The prevalence of obesity was quite
low compared with that in previous reports from
Western countries [1-4]. Significant differences in pa-
tient characteristics were observed with regard to age,
sex disparity, total nucleated cells (TNCs) per body
weight, and primary disease. The low-BMI group
Table 1. Patient Characteristics
n (%)
P value
BMI < 18 kg/m2 18 # BMI <25 kg/m2 25 # BMI < 30 kg/m2 30 kg/m2 # BMI
(n 5 295) (n 5 2906) (n 5 565) (n 5 61)
Recipient age, years
< 30 116 (39) 734 (25) 90 (16) 14 (23) < .0001
30 # age < 50 121 (41) 1473 (51) 322 (57) 36 (59)
> 50 58 (20) 699 (24) 153 (27) 11 (18)
Donor age, years
< 40 217 (74) 2099 (72) 385 (68) 38 (62) .27
$ 40 75 (25) 741 (25) 162 (29) 18 (30)
Sex, donor/recipient
Match 181 (61) 1833 (63) 374 (66) 39 (64) < .0001
Male/female 70 (24) 519 (18) 87 (15) 9 (15)
Female/male 43 (16) 495 (17) 87 (15) 9 (15)
TNC ( 108/kg)
TNC < 3.0 12 (4) 323 (11) 160 (28) 31 (51) < .0001
3.0 # TNC< 5.0 60 (20) 1085 (37) 267 (47) 16 (26)
5.0 # TNC 187 (63) 1191 (41) 78 (14) 1 (2)
Year of transplantation
1998 12 (4) 83 (3) 11 (2) 0 (0) .18
1999 21 (7) 248 (9) 39 (7) 0 (0)
2000 26 (9) 363 (12) 81 (14) 7 (11)
2001 43 (15) 398 (14) 74 (13) 7 (11)
2002 47 (16) 409 (14) 72 (13) 14 (23)
2003 50 (17) 404 (14) 87 (15) 10 (16)
2004 40 (14) 463 (16) 88 (16) 12 (20)
2005 56 (19) 538 (19) 113 (20) 11 (18)
Diagnosis
Acute leukemia 186 (63) 1469 (51) 304 (54) 29 (48) .02
CR1/CR2/>CR2 81/33/65 594/301/541 113/79/107 7/4/18
Chronic leukemia 30 (10) 449 (15) 84 (15) 13 (21)
CP1/CP2/AP/BC 16/5/5/3 251/66/65/53 53/8/12/11 5/3/3/2
MDS/MPD 37 (13) 462 (16) 87 (15) 11 (18)
RA/RAEB/others 7/12/10 99/155/166 25/33/20 7/3/1
ML 35 (12) 400 (14) 62 (11) 4 (7)
CR/>CR 10/19 138/230 24/33 1/3
MM 5 (2) 56 (2) 10 (2) 0 (0)
CR/>CR 1/1 10/33 1/7 0/0
Disease stage*
Standard 110 (37) 1034 (36) 202 (36) 19 (31) .67
High 158 (54) 1686 (58) 324 (57) 38 (62)
Blood type disparity
Match 146 (49) 1477 (51) 276 (49) 28 (46) .98
IA 8 (3) 103 (4) 18 (3) 2 (3)
MA 71 (24) 650 (22) 127 (22) 13 (21)
MI 65 (22) 586 (20) 121 (21) 14 (23)
HLA disparity
HLA allele match 185 (63) 1660 (57) 342 (61) 36 (59) .01
HLA allele mismatch 70 (24) 857 (29) 149 (26) 18 (30)
1 allele mismatch 59 (20) 728 (25) 118 (21) 11 (18)
2 allele mismatch 10 (3) 116 (4) 31 (5) 6 (10)
3 allele mismatch 1 (0) 13 (0) 0 (0) 1 (2)
Conditioning regimen
Conventional 235 (80) 2308 (79) 443 (78) 52 (85) .25
Reduced-intensity 59 (20) 539 (19) 105 (19) 5 (8)
TBI for conditioning
No 80 (27) 654 (23) 146 (26) 12 (20) .14
Yes 214 (73) 2188 (75) 402 (71) 45 (74)
ATG for conditioning
No 268 (91) 2670 (92) 517 (92) 55 (90) .21
Yes 23 (8) 155 (5) 25 (4) 2 (3)
GVHD prophylaxis
CSP-based 137 (46) 1141 (39) 226 (40) 16 (26) .19
TAC-based 153 (52) 1651 (57) 312 (55) 39 (64)
Others 3 (1) 48 (2) 7 (1) 2 (3)
Comorbidity
Liver dysfunction
No 239 (81) 2436 (84) 481 (85) 49 (80) .78
Yes 41 (14) 360 (12) 66 (12) 7 (11)
(Continued )
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Table 1. (Continued )
n (%)
P value
BMI < 18 kg/m2 18 # BMI <25 kg/m2 25 # BMI < 30 kg/m2 30 kg/m2 # BMI
(n 5 295) (n 5 2906) (n 5 565) (n 5 61)
Renal dysfunction
No 273 (93) 2706 (93) 528 (93) 54 (89) .90
Yes 7 (2) 90 (3) 19 (3) 2 (3)
Heart dysfunction
No 260 (88) 2601 (90) 519 (92) 54 (89) .32
Yes 20 (7) 195 (7) 28 (5) 2 (3)
Pulmonary dysfunction
No 267 (91) 2709 (93) 528 (93) 56 (92) .27
Yes 13 (4) 87 (3) 19 (3) 0 (0)
*Disease stage: Standard risk stage included CR1 in acute leukemia, first chronic phase in CML, and CR1 in lymphoma. Others were classified as high-risk
stage.
76 Biol Blood Marrow Transplant 15:73-82, 2009S. Fuji et al.included more young patients, patients receiving high
TNCs per body weight, patients with acute leukemia,
and male patients with a female donor.Figure 1. Probability of grade II-IV acute GVHD (A) and grade III-IV
acute GVHD (B).Clinical Outcomes
The incidence of grade II-IV acute GVHD was
42% in the low-BMI group, 45% in the normal-BMI
group, 48% in the overweight group, and 58% in the
obesity group (Figure 1A). Thus, increased BMI was
significantly associated with a higher incidence of
grade II-IV acute GVHD (P 5 .03 by the log-rank
trend test). Other factors associated with a higher inci-
dence of grade II-IV acute GVHD were HLA allele
disparity, GVHD prophylaxis with CSP (vs with
TAC), and donor age$ 40 years. Multivariate analysis
showed that pretransplantation BMI tended to be as-
sociated with an increased risk of grade II-IV acute
GVHD (P 5 .07, log-rank trend test) (Table 2). The
incidence of grade III-IV acute GVHD was 17% in
the low-BMI group, 17% in the normal-BMI group,
19% in the overweight group, and 25% in the obesity
group (Figure 1B). An increase in BMI tended to be as-
sociated with a higher incidence of grade III-IV acute
GVHD, but this trend was not significant (P 5 .087,
log-rank trend test). Multivariate analysis showed no
association between pretransplantation BMI and the
incidence of grade III-IV acute GVHD (P 5 .19,
log-rank trend test) (Table 3).
Nonrelapse mortality was 29% in the low-BMI
group, 31% in the normal-BMI group, 32% in the
overweight group, and 40% in the obesity group at 1
year after BMT (P 5 .19, log-rank trend test)
(Figure 2A). Overall survival was 61% in the low-
BMI group, 58% in the normal-BMI group, 59% in
the overweight group, and 53% in the obesity group
at 1 year after BMT (P 5 .98, log-rank trend test)
(Figure 2B). Progression-free survival was 54%,
52%, 56%, and 47% (P 5 .72, log-rank trend test),and the relapse rate was 24%, 24%, 18%, 21%, respec-
tively, in the 4 groups at 1 year after BMT (P5 .04 by
log-rank trend test) (Figure 2C and D). The incidence
of systemic infectious diseases, including bacterial,
fungal, and viral infections, was 39%, 43%, 46%,
and 59%, respectively, in the 4 groups (Figure 3). Obe-
sity was significantly associated with increased inci-
dence of infectious disease compared with normal
Table 2. Univariate and Multivariate Analyses of Risk Factors for Grade II-IV Acute GVHD
Covariates
Univariate Analysis Multivariate Analysis
HR 95% CI P value HR 95% CI P value
Recipient BMI
18 # BMI < 25 kg/m2 1.00 .026* 1.00 .066*
BMI < 18 kg/m2 0.91 0.75 to 1.10 1.06 0.85 to 1.31
25 # BMI < 30 kg/m2 1.11 0.97 to 1.27 1.19 0.93 to 1.52
30 # BMI kg/m2 1.28 0.89 to 1.85 1.29 0.82 to 2.03
Recipient age, years
<30 1.00 .85*
30 # age < 50 1.00 0.88 to 1.13
$ 50 0.99 0.86 to 1.14
Donor age, years
< 40 1.00 < .0001 1.00 < .0001
$ 40 1.30 1.17 to 1.45 1.28 1.13 to 1.44
Sex, donor/recipient
Match 1.00 .053 1.00 .20
Male/female 1.12 0.98 to 1.27 1.09 0.95 to 1.26
Female/male 1.15 1.01 to 1.32 1.12 0.97 to 1.30
TNC ( 108/kg)
TNC <3.0 1.00 .76*
3.0 # TNC < 5.0 1.03 0.88 to 1.20
5.0 # TNC 0.99 0.85 to 1.16
Diagnosis
Acute 1.00 .28
Chronic 1.08 0.93 to 1.24
MDS/MPD 1.01 0.87 to 1.16
ML 1.17 1.01 to 1.35
MM 0.92 0.62 to 1.36
Blood type disparity
M 1.00 .15 1.00 .49
IA 1.19 0.92 to 1.55 1.14 0.85 to 1.52
MA 1.03 0.90 to 1.16 1.02 0.89 to 1.17
MI 1.14 1.00 to 1.29 1.11 0.96 to 1.27
HLA disparity
HLA allele match 1.00 < .0001 1.00 < .0001
HLA 1 allele mismatch 1.30 1.16 to 1.47 1.36 1.21 to 1.54
HLA 2 allele mismatch 1.49 1.18 to 1.88 1.51 1.19 to 1.93
HLA 3 allele mismatch 2.23 1.16 to 4.30 2.23 1.15 to 4.31
Conditioning regimen:
TBI for conditioning
No 1.00 .67
Yes 0.98 0.87 to 1.10
Intensity of conditioning:
Conventional 1.00 .42
Reduced-intensity 0.95 0.84 to 1.08
ATG for conditioning
No 1.00 .58
Yes 0.94 0.75 to 1.17
GVHD prophylaxis
CSP-based 1.00 .025 1.00 .0003
TAC-based 0.89 0.80 to 0.98 0.80 0.71 to 0.89
Others 1.21 0.84 to 1.75 0.99 0.66 to 1.49
Comorbidity
Liver dysfunction
No 1.00 .52
Yes 0.95 0.82 to 1.11
Renal dysfunction
No 1.00 .84
Yes 1.03 0.77 to 1.38
Heart dysfunction
No 1.00 .58
Yes 0.94 0.77 to 1.16
Lung dysfunction
No 1.00 .15 1.00 .09
Yes 1.22 0.93 to 1.60 1.29 0.96 to 1.74
*The log-rank trend test was used for calculating P values.
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Table 3. Univariate and Multivariate Analyses of Risk Factors for Grade III-IV Acute GVHD
Univariate Analysis Multivariate Analysis
Covariate HR 95% CI P value HR 95% CI P value
Recipient BMI
18 # BMI < 25 kg/m2 1.00 .086* 1.00 .19*
BMI < 18 kg/m2 0.99 0.73 to 1.35 1.01 0.72 to 1.43
25 # BMI < 30 kg/m2 1.16 0.94 to 1.45 1.16 0.79 to 1.72
30 # BMI kg/m2 1.56 0.90 to 2.71 1.42 0.70 to 2.87
Recipient age, years
< 30 1.00 .97*
30 # age <50 0.98 0.81 to 1.19
$ 50 1.00 0.79 to 1.25
Donor age, years
< 40 1.00 < .0001 1.00 < .0001
$ 40 1.52 1.28 to 1.79 1.53 1.27 to 1.84
Sex, donor/recipient
Match 1.00 .057 1.00 .15
Male/female 1.21 0.99 to 1.49 1.13 0.90 to 1.42
Female/male 1.23 1.00 to 1.51 1.24 0.99 to 1.56
TNC ( 108/kg)
TNC < 3.0 1.00 .56*
3.0 < TNC < 5.0 0.90 0.71 to 1.15
5.0 < TNC 0.91 0.72 to 1.16
Diagnosis
Acute leukemia 1.00 .66
Chronic leukemia 1.13 0.90 to 1.41
MDS/MPD 0.99 0.78 to 1.24
ML 0.98 0.77 to 1.26
MM 0.71 0.35 to 1.43
Blood type disparity
M 1.00 .55
IA 1.04 0.67 to 1.61
MA 1.11 0.91 to 1.13
MI 1.15 0.94 to1.40
HLA disparity
HLA allele match 1.00 .0002 1.00 < .0001
HLA 1 allele mismatch 1.36 1.13 to 1.64 1.43 1.18 to 1.74
HLA 2 allele mismatch 1.57 1.10 to 2.24 1.57 1.07 to 2.30
HLA 3 allele mismatch 1.49 0.48 to 4.66 1.47 0.47 to 4.60
Conditioning regimen
TBI for conditioning
No 1.00 .49
Yes 0.94 0.78 to 1.13
Intensity of conditioning regimen
Conventional 1.00 .29
Reduced-intensity 1.11 0.91 to 1.36
ATG for conditioning
No 1.00 .26
Yes 0.80 0.55 to 1.18
GVHD prophylaxis
CSP-based 1.00 .029 1.00 .02
TAC-based 0.93 0.79 to 1.10 0.81 0.67 to 0.97
Others 1.78 1.09 to 2.91 1.27 0.71 to 2.28
Comorbidity
Liver dysfunction
No 1.00 .95
Yes 0.99 0.78 to 1.27
Renal dysfunction
No 1.00 .20
Yes 1.32 0.87 to 1.99
Heart dysfunction
No 1.00 .26
Yes 0.82 0.57 to 1.16
Lung dysfunction
No 1.00 .11 1.00 .20
Yes 1.39 0.93 to 2.07 1.36 0.86 to 2.16
*The log-rank trend test was used for calculating P values.
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Figure 2. Probability of nonrelapse mortality (A), progression-free survival (B), overall survival (C), and relapse/progression (D).
Figure 3. Incidence of systemic infections.
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[CI]5 1.1 to 3.2; P5 .02). The incidence of liver dys-
function, including sinusoidal occlusive syndrome, was
19% in the low-BMI group, 20% in the normal-BMI
group, 21% in the overweight group, and 25% in the
obesity group; the differences were not statistically
significant. The incidence of interstitial pneumonia,
excluding obvious infectious diseases such as cytomeg-
alovirus or Pneumocystis jirovecii pneumonia, was 13%
in the low-BMI group, 13% in the normal-BMI group,
12% in the overweight group, and 15% in the obesity
group; again, the differences are not statistically signi-
ficant. The causes of death are given in Table 4. More
infections and GVHD-related deaths were seen in the
obesity group. If only early mortality is considered,
then the nonrelapse mortality within 100 days was
17% in the low-BMI group, 18% in the normal-BMI
group, 17% in the overweight group, and 25% in the
obesity group. Obesity tended to be associated with
greater early nonrelapse mortality, but this difference
was not statistically significant (P 5 .83). The inci-
dence of infection-related mortality within 100 days
was 5%, 5%, 4% and 8%, respectively, in the 4 groups.
Bacterial infection was the main cause of infection-
related mortality, with 6 cases (40%) in the low-BMI
group, 91 cases (67%) in the normal-BMI group, 17
cases (74%) in the overweight group, and 3 cases
(60%) in the obesity group.
To investigate whether pretransplantation BMI
had an additional impact on outcome in the patients
who developed acute GVHD, we stratified the patients
according to the grade of acute GVHD and analyzed
the association between pretransplantation BMI andearly nonrelapse mortality. We found that pretrans-
plantation BMI had no additional impact on early non-
relapse mortality.DISCUSSION
Both obesity and malnutrition are considered risk
factors for complications, especially infectious dis-
eases. To elucidate the impact of pretransplantation
BMI on the clinical outcome, in this study we retro-
spectively reviewed the data of patients who underwent
unrelated BMT, stratified according to recipient BMI,
and found results similar to those reported previously
[1,2]. The present study has an obvious limitation,
Table 4. Causes of Death
BMI < 18 kg/m2 18 # BMI < 25 kg/m2 25 # BMI < 30 kg/m2 30 kg/m2 # BMI
(n 5 295) (n 5 2906) (n 5 565) (n 5 61)
Relapse, n (%) 66 (22%) 609 (21%) 95 (17%) 8 (13%)
Nonrelapse mortality, (%) 97 (33%) 988 (34%) 206 (36%) 24 (39%)
Infection, n (%) 25 (8%) 276 (9%) 56 (10%) 8 (13%)
Bacterial, n 13 151 34 4
Fungal, n 3 37 7 1
Viral, n 4 39 5 1
Mixed, n 2 16 3 1
Others, n 3 33 6 1
Acute GVHD, n (%) 9 (3%) 78 (3%) 26 (5%) 4 (7%)
Chronic GVHD, n (%) 4 (1%) 45 (2%) 13 (2%) 2 (3%)
Graft failure, n (%) 2 (1%) 31 (1%) 6 (1%) 1 (2%)
Organ dysfunction, n (%) 47 (16%) 395 (14%) 83 (15%) 7 (11%)
Others, n (%) 10 (3%) 163 (6%) 22 (4%) 2 (3%)
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justment of chemotherapy, which is critical for analyz-
ing the incidence of organ dysfunction. Dosing
schemes for preparative chemotherapy regimens vary
widely among transplantation centers. In addition,
centers differ in their use of ideal body weight, actual
body weight, and compensatory calculations that yield
doses between the actual and ideal weights [19,20]. An-
other limitation of this study is that low prevalence of
obesity in Japan makes the study’s statistical power less
reliable. For example, patients with morbid obesity
(BMI. 35 kg/m2), considered a significant comorbid-
ity in a hematopoietic cell transplantation-specific co-
morbidity index, are quite rare in Japan [21]. Similar
analyses need to be performed in Western countries
to clarify the impact of obesity, especially morbid obe-
sity, after allogeneic HSCT.
Our findings demonstrate that obesity is associated
with an increased risk of infectious disease compared
with normal weight. Hyperglycemia, caused primarily
by insulin resistance in obesity, can lead to increased
incidence of infectious disease. As reported by Sheean
et al. [22], hyperglycemia after HSCT may be a risk
factor for infectious disease. Recently, Derr et al.
[23] reported an association between hyperglycemia
before a neutropenic period and increased risk of infec-
tious diseases during a neutropenic period after
HSCT. In our study, an increased incidence of acute
GVHD was associated with an increased risk of infec-
tious disease. On the other hand, low BMI, which sug-
gests the presence of malnutrition, was not associated
with an increased risk of infectious diseases or trans-
plantation-related mortality, inconsistent with previ-
ous reports [10,11]. This could be because the
incidence of acute GVHD was lower and the dose of
TNC per body weight was higher in the low-BMI
group. Even if we further divide the BMI\ 18 kg/
m2 group into 3 subgroups (BMI\ 16 kg/m2, 16 #
BMI \ 17 kg/m2, and 17 # BMI \ 18 kg/m2), we
find no differences in the incidence of acute GVHD
or infectious disease, or in clinical outcomes (datanot shown). It is possible that in the Japanese popula-
tion, BMI\18 kg/m2may not directly reflect amalnu-
tritional status.
Importantly, our findings also suggest an associa-
tion between increased BMI and a significantly in-
creased incidence of acute GVHD grade II-IV. This
observation is based on multiple factors, and no single
clear scientific explanation for it exists, but several
mechanisms can be hypothesized. First, the dose of
the conditioning regimen and GVHD prophylaxis
could be improperly adjusted in obese patients, possi-
bly leading to increased tissue damage or poorer
GVHD prophylaxis and, ultimately, a higher inci-
dence of acute GVHD. With regard to the condition-
ing regimen, the relapse rate was lower in the
overweight and obese patients compared with the
low-BMI and normal-BMI patients, but the incidence
of regimen-related toxicity (ie, liver dysfunction and
interstitial pneumonitis) did not differ significantly
among these groups. With regard to GVHD prophy-
laxis, there might not have been any significant differ-
ence in drug exposure, because dose adjustment of the
calcineurin inhibitor usually is done through serial
monitoring of drug concentration. Second, the stem
cell dose could influence the incidence of acute
GVHD. But in this study, the stem cell dose was ana-
lyzed independently, and no association was found be-
tween stem cell dose and the incidence of acute
GVHD. Third, there was an obvious selection bias
in each group. For example, it is possible that obese
patients may be less likely to find an unrelated donor
with an adequate dose of cells for transplantation.
While the donor search continued, the number of che-
motherapy courses could increase, and the patient’s
general condition (including disease status and organ
function) could become worse. Finally, even though
there were no direct data regarding glucose levels in
this study, obesity is likely associated with hyperglyce-
mia [7-9], possibly resulting in elevated levels of sev-
eral cytokines [24-27], inducing a vicious cycle [28-
30]. Our group previously reported an association
Biol Blood Marrow Transplant 15:73-82, 2009 81Obesity and Complications after Unrelated BMTbetween hyperglycemia during neutropenia and the
development of acute GVHD [6], possibly due to
the augmented production of cytokines stimulated
by the conditioning regimen. Furthermore, recently
it has become clear that adipocytokines, which are
secreted mainly from adipocytes, play important roles
in the control of immunity [31-33]. In particular, the
level of leptin has been found to be proportional to
body fat weight and to affect T regulatory cell
(Treg) proliferation and function [34,35]. Thus, it
could be hypothesized that in obese patients, a higher
leptin level suppresses Treg activity, increasing the
risk of acute GVHD. These mechanisms are based
on the results of animal models, however, and await
confirmation in human studies.
The clinical significance of our findings merits
careful consideration, because pretransplantation
BMI is one of the few factors that can be properly man-
aged and corrected during the unstable, fast-moving
pretransplantation period. On the other hand, malnu-
trition can be corrected by appropriate nutritional sup-
port, and obesity can be controlled through an
appropriate diet and exercise program during chemo-
therapy. This study suggests that such a pretransplan-
tation nutritional support program can improve
clinical outcomes after allogeneic BMT.
In conclusion, this retrospective analysis of registra-
tion data found an association between pretransplanta-
tion obesity and increased risk of infectious disease,
possibly leading to increased risk of mortality. Although
body weight is affected by multiple clinical factors, the
effect of obesity on clinical outcome, as suggested
here, needs to be confirmed by a prospective study to
identify better patient management approaches.ACKNOWLEDGMENTS
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